Page last updated: 2024-11-03

propranolol and Lewy Body Disease

propranolol has been researched along with Lewy Body Disease in 1 studies

Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.

Lewy Body Disease: A neurodegenerative disease characterized by dementia, mild parkinsonism, and fluctuations in attention and alertness. The neuropsychiatric manifestations tend to precede the onset of bradykinesia, MUSCLE RIGIDITY, and other extrapyramidal signs. DELUSIONS and visual HALLUCINATIONS are relatively frequent in this condition. Histologic examination reveals LEWY BODIES in the CEREBRAL CORTEX and BRAIN STEM. SENILE PLAQUES and other pathologic features characteristic of ALZHEIMER DISEASE may also be present. (From Neurology 1997;48:376-380; Neurology 1996;47:1113-1124)

Research Excerpts

ExcerptRelevanceReference
"These included progressive supranuclear palsy (PSP; n = 2), drug-induced parkinsonism (n = 2), idiopathic Parkinson disease (PD; n = 1), and basal ganglia status cribrosus (n = 1)."1.32Essential tremor course and disability: A clinicopathologic study of 20 cases. ( Rajput, A; Rajput, AH; Robinson, CA, 2004)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Rajput, A1
Robinson, CA1
Rajput, AH1

Other Studies

1 other study available for propranolol and Lewy Body Disease

ArticleYear
Essential tremor course and disability: A clinicopathologic study of 20 cases.
    Neurology, 2004, Mar-23, Volume: 62, Issue:6

    Topics: Adrenergic beta-Antagonists; Age of Onset; Aged; Antiparkinson Agents; Disability Evaluation; Diseas

2004